Phaseline

Companies › Suven Life Sciences

Suven Life Sciences: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 3; Neurology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Masupirdine (SUVN-502)
Serotonin 6 (5-HT6) receptor antagonist
HTR6Phase 3AgitationDec 2026
Suvn-G3031
Histamine H3 receptor inverse agonist
HRH3Phase 3NarcolepsyNov 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05397639Masupirdine (SUVN-502)Phase 3AgitationNeurologyDec 2026
NCT07540364Suvn-G3031Phase 3NarcolepsyNeurologyNov 2027

Targets

HRH3 (1) HTR6 (1)

Companies with the same targets

Harmony Biosciences Management

Companies built like this

Bigespas JYAMS PET Research & Development Longboard Pharmaceuticals TriGemX Bio Zogenix

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.